BTX 1503
Acne
Phase 2Active Clinical Development
Key Facts
About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a clinical-stage biotech focused on developing and commercializing novel dermatology and antimicrobial therapeutics. Its core achievement is the FDA approval and US launch of Sofdra™, a first-in-class topical anticholinergic for excessive underarm sweating, which is also approved in Japan and South Korea. The company's strategy leverages a dual-technology platform—Permetrex™ for enhanced skin delivery and synthetic CBD for its anti-inflammatory and antimicrobial properties—to address large, underserved markets. With a lean, US-focused commercial operation and an experienced leadership team, Botanix aims to transform its pipeline into a portfolio of high-value dermatology products.
View full company profileTherapeutic Areas
Other Acne Drugs
| Drug | Company | Phase |
|---|---|---|
| Novel Anti-acne Therapeutics (with Curl Bio) | ZenBio | Pre-clinical |
| B244 | AOBiome | Phase 2 |
| ADA-308 | Aranda Pharma | Pre-clinical |
| Living Skin Probiotic Program | S-biomedic | Pre-clinical/Clinical |
| Vincobiosis® Acneic | Laboratorio Reig Jofre | Launched |
| Pyrilutamide | Kintor Pharma | Phase 2 |